Boston Trust Walden Corp Sells 69,924 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Boston Trust Walden Corp trimmed its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,513,975 shares of the biotechnology company's stock after selling 69,924 shares during the period. Boston Trust Walden Corp owned approximately 1.45% of Corcept Therapeutics worth $70,067,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Park Place Capital Corp acquired a new position in Corcept Therapeutics during the second quarter worth about $32,000. Atwood & Palmer Inc. acquired a new position in Corcept Therapeutics during the second quarter worth about $35,000. Kathleen S. Wright Associates Inc. acquired a new position in Corcept Therapeutics during the third quarter worth about $36,000. FinTrust Capital Advisors LLC grew its holdings in Corcept Therapeutics by 318.7% during the first quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 1,348 shares during the period. Finally, Blue Trust Inc. grew its holdings in Corcept Therapeutics by 125.4% during the second quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company's stock worth $115,000 after acquiring an additional 1,962 shares during the period. 93.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on CORT shares. Sandler O'Neill reaffirmed a "buy" rating on shares of Corcept Therapeutics in a report on Friday, October 18th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $38.00 target price on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Piper Sandler increased their price target on Corcept Therapeutics from $38.00 to $67.00 and gave the company an "overweight" rating in a research report on Wednesday, September 18th. HC Wainwright increased their price target on Corcept Therapeutics from $45.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Finally, Truist Financial increased their price target on Corcept Therapeutics from $65.00 to $76.00 and gave the company a "buy" rating in a research report on Monday, September 30th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $65.25.

Corcept Therapeutics Stock Performance

Shares of NASDAQ:CORT traded up $0.04 during midday trading on Friday, reaching $47.28. The company had a trading volume of 933,325 shares, compared to its average volume of 1,183,725. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $50.07. The firm has a market cap of $4.92 billion, a price-to-earnings ratio of 44.60 and a beta of 0.46. The company has a fifty day simple moving average of $41.05 and a two-hundred day simple moving average of $33.79.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings data on Monday, July 29th. The biotechnology company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.09. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The firm had revenue of $163.80 million during the quarter, compared to analyst estimates of $155.14 million. During the same period last year, the company posted $0.25 EPS. The business's quarterly revenue was up 39.1% compared to the same quarter last year. Analysts expect that Corcept Therapeutics Incorporated will post 1.12 EPS for the current year.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Gary Charles Robb sold 3,101 shares of the firm's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $35.71, for a total transaction of $110,736.71. Following the completion of the sale, the insider now directly owns 23,190 shares in the company, valued at approximately $828,114.90. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider Gary Charles Robb sold 3,101 shares of Corcept Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $35.71, for a total transaction of $110,736.71. Following the completion of the sale, the insider now directly owns 23,190 shares in the company, valued at $828,114.90. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Guyer sold 10,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $38.67, for a total value of $386,700.00. Following the sale, the insider now owns 6,039 shares of the company's stock, valued at approximately $233,528.13. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,251 shares of company stock worth $1,365,292. 20.50% of the stock is currently owned by company insiders.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.